Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2010

Commission File Number 0-28564

(Translation of registrant s name into English)

(Address of principal executive office)

check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule

Indicate by check mark if the registrant is

submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

On May 3, 2010, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) issued a press release announcing its unaudited financial

results for the quarter ended March 31, 2010. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

QIAGEN has regularly reported adjusted results, which are considered non-GAAP financial measures, to give additional insight into our

financial performance as a supplement to understand, manage, and evaluate our business results and make operating decisions. Adjusted results should be considered in addition to the reported results prepared in accordance with U.S. generally

accepted accounting principles, but should not be considered as a substitute. Reconciliations of reported results to adjusted results are included in the tables accompanying the press release. We believe certain items should be excluded from

adjusted results when they are outside of our ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Company s competitors and our own prior periods.

The non-GAAP financial measures used in this press release are non-GAAP operating income, pre-tax income, net income and diluted earnings

per share. These adjusted results exclude costs related to amortization of acquired intangible assets, impairment losses, share-based payment expenses, acquisition, integration and restructuring expenses, including inventory fair value adjustments

related to business acquisitions, as well as non-recurring charges or income. Management views these costs as not indicative of the profitability or cash flows of our ongoing or future operations and therefore considers the adjusted results as a

supplement, and to be viewed in conjunction with, the reported GAAP results.

We also consider results on a constant currency

basis. Our functional currency is the U.S. dollar and our subsidiaries functional currencies are the local currency of the respective countries in which they are headquartered. A significant portion of our revenues and expenses is denominated

in euros and currencies other than the United States dollar. Management believes that analysis of constant currency period-over-period changes is useful because changes in exchange rates can affect the growth rate of net sales and expenses,

potentially to a significant degree. Constant currency figures are calculated by translating the local currency actual results in the current period using the average exchange rates from the previous year s respective period instead of the

We use non-GAAP and constant currency financial measures internally in our planning, forecasting and

reporting, as well as to measure and compensate our employees. We also use the adjusted results when comparing to our historical operating results, which have consistently been presented on an adjusted basis.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned, thereunto duly authorized.

QIAGEN Reports Strong First Quarter 2010 Results

Venlo, The Netherlands, May 3, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations

for its quarter ended March 31, 2010.

Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010

exceeded the guidance provided by the Company on February 9, 2010.

First Quarter 2010 Results

QIAGEN s First Quarter 2010

For information on the adjusted figures, please refer to the reconciliation table

accompanying this release.

The Company reported that consolidated net sales for its first quarter of 2010 increased 20% to $264.4

million from $220.9 million for the same quarter of 2009. Excluding the favorable impact from foreign currency exchange rates, net sales for the first quarter 2010 would have increased by 14% from the first quarter of 2009. Reported operating income

for the quarter increased 21% to $44.7 million from $37.0 million in the same quarter of 2009, and net income for the quarter increased 34% to $33.0 million from $24.7 million in the same quarter of 2009. Diluted earnings per share for the first

quarter increased 17% to $0.14 in 2010 (based on 241.9 million weighted average shares and share equivalents outstanding) from $0.12 in 2009 (based on 203.2 million weighted average shares and share equivalents outstanding).

On an adjusted basis, first quarter operating income increased 24% to $73.6 million in 2010 from $59.1 million in 2009, and first quarter adjusted net

income increased 22% to $49.3 million in 2010 from $40.3 million in 2009. Adjusted diluted earnings per share were $0.20 in the first quarters of both, 2010 and 2009.

QIAGEN s first quarter 2010 results include the results of operations from the Company s recent acquisitions, the most significant of which

were SABiosciences Corporation, acquired in December 2009, and DxS Ltd., acquired in September 2009. Reconciliations of reported results determined in accordance with generally accepted accounting principles (GAAP) to adjusted results are included

in the tables accompanying this release.

QIAGEN experienced a successful start into 2010, said Peer Schatz, QIAGEN s Chief

Executive Officer. We recorded strong revenue and adjusted net income growth and continued to see exciting momentum in our strategic position. We launched 14 new products in the area of Sample & Assay Technologies and recorded once

again an excellent 4% of sales from products launched within the last 12 months. We are also managing an exceptionally strong pipeline of new products and are preparing for the 2010 launches of many strategically important products including the

QIAensemble and QIAsymphony-RGQ platforms in Europe together with their broad menu of regulated assays for prevention, profiling and personalized healthcare.

The first quarter of 2010 was a quarter of very important strategic moves, including in molecular diagnostics. In the field of prevention we extended our

support of a cervical cancer screening program for underprivileged women with the Cancer Foundation in China. In the area of profiling we established an agreement for a respiratory pathogen multiplex assay with Celera and in personalized healthcare

we were able to acquire an exclusive license for biomarker PI3K from John Hopkins University, a gene discussed as a key biomarker for use in companion diagnostics with certain cancer treatments and entered into an agreement to develop a companion

diagnostic with the pharmaceutical company Pfizer for brain tumor patients. In the field of point of need testing we expanded our instrumentation platform with a portable, battery operated, ultra-fast time to result , multiplex UV and

fluorescence optical measurement device through the acquisition of ESE GmbH for use in medical emergency and critical care testing and in industrial environments.

In addition, we experienced good growth in product sales to our customers in academia, the pharmaceutical

industry and in applied markets.

We are very well positioned to take advantage of the growth opportunities we are seeing in our target

markets and are fully on track to achieve our annual targets.

We are pleased with our financial performance in this first quarter

of 2010. Reported revenues were at the high end of, and adjusted earnings per share exceeded our expectations for the first quarter of 2010, said Roland Sackers, QIAGEN s Chief Financial Officer. Revenue growth for the first quarter

was 20% fueled by a strong organic growth of 11% and a positive contribution of 5% from acquisitions. In addition we saw high growth rates of 24% in our adjusted operating income and of 22% in our adjusted net income.

Our consumable portfolio represented approximately 86% of our total net sales and contributed 15% growth (10% at constant exchange rates). QIAGEN s

instrumentation products contributed approximately 14% of our total net sales and continued to show high growth rates of 46% (37% at constant exchange rates). Highlights within our instrumentation portfolio were sample and assay technology

automation platforms such as our EZ1 Advanced XL, the QIAsymphony, the QIAgility, the Pyromark and the Rotor-Gene Q. The largest revenue share we recorded in the first quarter 2010 was in sales to customers in molecular diagnostics (approximately

45% of total revenues) followed by sales to customers in academia (approximately 27% of total revenues), in pharma (approximately 21% of total revenues) and in applied testing (approximately 7% of total revenues).

We are reiterating our guidance for fiscal year 2010 based on foreign currency exchange rates as of January 31, 2010, with expected revenues

between $1,120 and $1,170 million and adjusted diluted earnings per share between $0.90 and $0.96.

QIAGEN Sample and Assay

Technologies Highlights

Conference Call and Webcast Details

Detailed information on QIAGEN s business and financial performance will be presented during its conference call on May 4, 2010 at 9:30am ET

(3:30pm CET). The corresponding presentation slides will be available for download on the Company s website at www.qiagen.com/goto/ConferenceCall. A webcast of the conference call will also be available at

www.qiagen.com/goto/ConferenceCall.

Use of Adjusted Results

QIAGEN has regularly reported adjusted results to give additional insight into its financial performance and has also considered results on a constant

currencies basis. Adjusted results should be considered in addition to the reported results prepared in accordance with generally accepted accounting principles, but should not be considered as a substitute. The Company believes certain items should

be excluded from adjusted results to provide additional insight into the Company s performance when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with the

Company s competitors and its own prior periods. Reconciliations of reported results to adjusted results are included in the tables accompanying this release.